Trial Profile

A Randomized, Open, Multicenter Phase II/III Trial to Compare the Efficacy and Safety of QL1706 and Carrilizumab Combined With Gemcitabine and Cisplatin in First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 12 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cisplatin (Primary) ; Gemcitabine (Primary) ; Iparomlimab/tuvonralimab (Primary) ; Camrelizumab
Indications Carcinoma; Nasopharyngeal cancer
Focus Therapeutic Use
Sponsors Qilu Pharmaceutical

06 Jun 2024 Results published in the Qilu Pharmaceutical Media Release
06 Jun 2024 According to a Qilu Pharmaceutical media release, data from this trial presented at The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
04 Jun 2024 Results (n=29) assessing safety and efficacy of QL1706 combined with chemotherapy as 1L treatment in R/M NPC presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com